Monday, January 3, 2011

Lancet: Aspirin and reduction in risk of cancer related mortality (Meta-Analysis)

In the Lancet this week there is an interesting article looking at the long term reduction in cancer related mortality in trials looking a daily aspirin use. The investigators performed an individual case meta-analysis of several trials and found a reduction in all cancer related mortality of 0.79 (odd-ratio). This held out to 20 years. The greatest benefit was seen in GI tumors, though it was not confined to them.


[Articles] Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials: "Daily aspirin reduced deaths due to several common cancers during and after the trials. Benefit increased with duration of treatment and was consistent across the different study populations. These findings have implications for guidelines on use of aspirin and for understanding of carcinogenesis and its susceptibility to drug intervention."

No comments: